Upon completion of the video presentation, to finish the activity and claim your credit, please click
here.
This activity has expired, credit is no longer available.
This activity is supported by an educational grant from Merck & Co.
Immunotherapy: Advances and Updates
Anthony J. Olszanski, MD, RPH
Fox Chase Cancer Center
Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
Stanford Cancer Institute
One of the greatest advances in oncology over the past decade has been the recognition of cell surface proteins that are shown to play a key role in tumor immunogenicity; mechanisms in which tumors are able to avoid immune surveillance and destruction. Although immunotherapy is a relatively new approach to anti-cancer treatment, it is being utilized across multiple tumor types. This program highlights the science behind immunotherapy, immune-related adverse side effects (irAEs), monitoring and managing irAEs, the role of biomarkers, and differentiating pseudo-progression from actual disease progression.
These CME/CE/CPE accredited activities are jointly provided by
